Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash & Equivalents (2020 - 2025)

Treace Medical Concepts' Cash & Equivalents history spans 6 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 5.66% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, down 5.66%, while the annual FY2025 figure was $10.7 million, 5.66% down from the prior year.
  • Cash & Equivalents reached $10.7 million in Q4 2025 per TMCI's latest filing, up from $7.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $119.6 million in Q2 2021 to a low of $7.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $38.1 million, with a median of $13.4 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 1060.81% in 2021, then crashed 88.15% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $105.8 million in 2021, then plummeted by 81.6% to $19.5 million in 2022, then tumbled by 33.33% to $13.0 million in 2023, then dropped by 12.57% to $11.4 million in 2024, then fell by 5.66% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Cash & Equivalents are $10.7 million (Q4 2025), $7.7 million (Q3 2025), and $8.1 million (Q2 2025).